Review of Ocular Toxicity Incidence and Mechanisms for Approved Antibody-Drug Conjugates

A review document compiling data on ocular toxicity reported during clinical development and postmarketing surveillance for all currently approved antibody-drug conjugates (ADCs). The text analyzes potential mechanisms, summarizes reported adverse events and their incidence, and explores mitigation strategies. It was authored by Junxiang Zhou and last updated on 2026-04-27.

Use Cases

• Summarizing incidence rates of ocular adverse events across approved ADCs based on the compiled clinical and postmarketing data.
• Analyzing potential biological mechanisms underlying ADC-associated ocular toxicity discussed in the review.
• Informing toxicity management strategies for early detection and monitoring based on the review's highlighted significance.
• Supporting drug development decisions on target selection and linker design to mitigate toxicity as explored in the review.

Strengths

• Focuses on a specific, under-prioritized toxicity (ocular) within a prominent therapeutic modality (ADCs).
• Compiles data from both clinical development and postmarketing surveillance phases for all approved ADCs.
• License is CC-BY-4.0, permitting broad reuse with attribution.

Limitations

• Data is presented as a review document (DOCX); the underlying structured data tables are not provided separately.
• The file size is 23.3 KB, indicating a limited textual scope rather than a large-scale dataset.
• Row and column counts are unknown, limiting assessment of data volume and structure.

Provenance

Source

figshare

Collection Method

Compilation and analysis from published clinical development and postmarketing surveillance reports.

Time Range

Covers the period up to the approval and use of all currently approved ADCs as of the review's writing.

Freshness

Last updated 2026-04-27 05:16:34.

Geography

Global, as it reviews approved ADCs internationally.